Landscape Capital Management L.L.C. Sells 21,703 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Landscape Capital Management L.L.C. cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 78.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,067 shares of the biotechnology company's stock after selling 21,703 shares during the period. Landscape Capital Management L.L.C.'s holdings in Exelixis were worth $202,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in EXEL. Tri Ri Asset Management Corp acquired a new stake in shares of Exelixis during the third quarter worth about $4,396,000. Blue Trust Inc. raised its stake in shares of Exelixis by 134.7% during the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock worth $476,000 after purchasing an additional 8,208 shares during the last quarter. Range Financial Group LLC acquired a new position in Exelixis during the fourth quarter worth $994,000. Allspring Global Investments Holdings LLC lifted its position in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after acquiring an additional 704,786 shares during the period. Finally, Inspire Investing LLC increased its position in shares of Exelixis by 25.0% in the fourth quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company's stock valued at $1,221,000 after buying an additional 7,331 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Trading Up 1.0 %

EXEL stock traded up $0.34 during mid-day trading on Monday, hitting $35.65. The stock had a trading volume of 289,117 shares, compared to its average volume of 2,167,999. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The company has a fifty day moving average of $36.16 and a 200 day moving average of $34.01. The stock has a market capitalization of $9.98 billion, a price-to-earnings ratio of 20.14, a PEG ratio of 1.13 and a beta of 0.57.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on EXEL shares. Barclays boosted their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. Morgan Stanley raised shares of Exelixis from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $30.00 to $40.00 in a research report on Monday, January 27th. Brookline Capital Management started coverage on Exelixis in a research report on Monday, December 23rd. They set a "buy" rating on the stock. Stifel Nicolaus raised their target price on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research note on Wednesday, February 12th. Finally, Guggenheim restated a "buy" rating and issued a $42.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis has a consensus rating of "Moderate Buy" and an average target price of $37.59.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 52,636 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company's stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock worth $5,177,234. Insiders own 2.85% of the company's stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.